Skip to content

Immunome IMNM Investment Proceeds

Investment Proceeds at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$67.97M+45.7%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$162.53M-12.8%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$177.29M+10.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$79.38M+1,384%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$101.48M+46.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$175.5K

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.24B+323%

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's investment proceeds?
Immunome (IMNM) reported investment proceeds of $0 in Q1 2026.
How has Immunome's investment proceeds changed year-over-year?
Immunome's investment proceeds decreased by 100.0% year-over-year, from $15M to $0.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.